EcoDrugPlus

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSSTUG00000031045
Gene Symbol: CACNA1AB
1 Cross references
183 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSSTUG00000049062
Gene Symbol: CACNB3A
1 Cross references
190 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSSTUG00000048102
Gene Symbol: CASR
3 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSSTUG00000035304
Gene Symbol: CACNA2D1
3 Cross references
219 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSSTUG00000033613
Gene Symbol: CACNA2D1
3 Cross references
219 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSSTUG00000035947
Gene Symbol: CACNA2D2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSSTUG00000043747
Gene Symbol: CACNA2D3
3 Cross references
217 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSSTUG00000029314
Gene Symbol: CACNA2D4
3 Cross references
233 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSSTUG00000007981
Gene Symbol: CACNA2D4
3 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSSTUG00000003138
Gene Symbol: CACNB2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSSTUG00000015348
Gene Symbol: CACNB2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSSTUG00000036026
Gene Symbol: CACNB3
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).